Glenmede Trust CO Na Vaxcyte, Inc. Transaction History
Glenmede Trust CO Na
- $18.2 Billion
- Q1 2025
A detailed history of Glenmede Trust CO Na transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Glenmede Trust CO Na holds 6,664 shares of PCVX stock, worth $274,623. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,664
Previous 6,645
0.29%
Holding current value
$274,623
Previous $543,000
53.78%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$605 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$494 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$493 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$410 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$247 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.44B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...